Investigating how aspirin affects weight and heart disease risk
Aspirin-triggered Specialized Pro-resolving Mediators in Increasing Weight and Atherosclerotic Cardiovascular Disease
This study is looking at how taking a small daily dose of aspirin might help improve heart health for people who are overweight or have artery problems, by reducing inflammation and other risks related to heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11045727 on NIH RePORTER |
What this research studies
This research explores the effects of daily low-dose aspirin on cardiovascular health, particularly in relation to body weight. It examines how aspirin, while primarily used to prevent blood clots, may also influence inflammation and cardiovascular risk factors in individuals with obesity and atherosclerosis. The study focuses on specialized lipid mediators that are produced when aspirin is taken, which may help reduce inflammation and improve heart health outcomes. By analyzing blood samples and health data, the research aims to uncover the relationship between aspirin use, body weight, and cardiovascular disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are overweight or have a history of cardiovascular disease.
Not a fit: Patients who are not overweight or do not have cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for using aspirin in preventing heart disease, especially in overweight individuals.
How similar studies have performed: Previous studies have shown that aspirin can reduce cardiovascular events in certain populations, but this specific approach focusing on body weight and inflammation is relatively novel.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Heffron, Sean Patrick — New York University School of Medicine
- Study coordinator: Heffron, Sean Patrick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.